FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Responses)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person THOMPSON STEPHEN B				2. Issuer Name and Ticker or Trading Symbol ACCESS PHARMACEUTICALS INC [accp]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) ACCESS PHARMACEUTICALS INC, 2600 STEMMONS FRWY STE 176				3. Date of Earliest Transaction (Month/Day/Year) 05/21/2008							Director				
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) X Form filed by One Reporting Person				
DALLAS, TX 752072107											Form filed by More than One Reporting Person				
(City) (State) (Zip)				Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year			2A. Deemed Execution Date, if r) (Month/Day/Year			(Instr. 8)		curities Acquir or Disposed of r. 3, 4 and 5) (A) or (D) F	(D) Owne Transa	Owned Following Reported Transaction(s) (Instr. 3 and 4)		(F I (Ownership form: Be Direct (D) or Indirect (In	Nature Indirect eneficial wnership nstr. 4)	
Reminder:	Report on a	separate line for eac		Derivati	ve S	Securities	s Ac	Persons win this for displays a		quired to ralid OMB o	espond control r	unless the		ed SEC 14	74 (9-02)
1. Title of Derivative Security (Instr. 3)	Conversion		3A. Deemed Execution Date, if any (Month/Day/Year)	Date, if Transaction of Expiration Date (Month/Day/Year)		7. Title and Amount of		8. Price of Derivative Security (Instr. 5)	9. Number o Derivative Securities Beneficially Owned Following Reported Transaction ((Instr. 4)	Ownership Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$ 3	05/21/2008		A		12,500		05/21/2009	05/21/2018	Common stock	12,500	\$ 3	147,500	D	
Stock option (right to buy)	\$ 3	05/21/2008		A		37,500		06/21/2009 ⁽¹⁾	05/21/2018	Common stock	37,500	\$ 3	185,000	D	
Repor	ting O	wners												·	

Barrandin - Oranga Nama / Addana	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
THOMPSON STEPHEN B ACCESS PHARMACEUTICALS INC 2600 STEMMONS FRWY STE 176 DALLAS, TX 752072107			Chief Financial Officer				

Signatures

Stephen B. Thompson	05/22/2008
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) After twelve months from the Grant Date options vest 2.0833% monthly, all options vested 48 months from the Grant Date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.